[go: up one dir, main page]

WO1996040075B1 - Procede de production a grande echelle avec melange instantane des composants et caracteristiques controlees de melange sequentiel - Google Patents

Procede de production a grande echelle avec melange instantane des composants et caracteristiques controlees de melange sequentiel

Info

Publication number
WO1996040075B1
WO1996040075B1 PCT/US1996/008782 US9608782W WO9640075B1 WO 1996040075 B1 WO1996040075 B1 WO 1996040075B1 US 9608782 W US9608782 W US 9608782W WO 9640075 B1 WO9640075 B1 WO 9640075B1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
protein
medicine
bag
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/008782
Other languages
English (en)
Other versions
WO1996040075A1 (fr
Filing date
Publication date
Priority claimed from US08/487,303 external-priority patent/US5716643A/en
Application filed filed Critical
Priority to AU60416/96A priority Critical patent/AU6041696A/en
Publication of WO1996040075A1 publication Critical patent/WO1996040075A1/fr
Publication of WO1996040075B1 publication Critical patent/WO1996040075B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

La présente invention concerne un procédé et un appareil pour la production à grande échelle de substances porteuses médicales in vivo pour administration médicale. Les réactifs sont préparésen solution et sont contenus chacun dans un sac. Des pompes et des chambres de mixage montés en série sont connectés aux sacs de réactifs. Les pompes sont réglées à des débits déterminés et activées selon une séquence prédéterminée selon des délais préétablis afin d'obtenir un mélange instantané des composants ainsi que descaractéristiques de mélange séquentiel contrôlées.
PCT/US1996/008782 1995-06-07 1996-06-05 Procede de production a grande echelle avec melange instantane des composants et caracteristiques controlees de melange sequentiel Ceased WO1996040075A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60416/96A AU6041696A (en) 1995-06-07 1996-06-05 Large scale production process with instantaneous component mixing and controlled sequential mixing characteristics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/487,303 US5716643A (en) 1995-06-07 1995-06-07 Large scale production of medicine coated crosslinked protein microspheres
US08/487,303 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040075A1 WO1996040075A1 (fr) 1996-12-19
WO1996040075B1 true WO1996040075B1 (fr) 1997-01-16

Family

ID=23935193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008782 Ceased WO1996040075A1 (fr) 1995-06-07 1996-06-05 Procede de production a grande echelle avec melange instantane des composants et caracteristiques controlees de melange sequentiel

Country Status (3)

Country Link
US (2) US5716643A (fr)
AU (1) AU6041696A (fr)
WO (1) WO1996040075A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
WO1998055105A1 (fr) * 1997-06-05 1998-12-10 Hemosphere, Inc. Microspheres enrobees de fibrinogene
US20030113237A1 (en) * 2001-08-15 2003-06-19 Third Wave Technologies, Inc. Polymer synthesizer
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
AU2003299722A1 (en) * 2002-12-17 2004-07-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
WO2006089012A2 (fr) * 2005-02-14 2006-08-24 Neurogesx, Inc. Dispositif pour l'apport d'agonistes de trpv1
WO2006105481A1 (fr) * 2005-03-30 2006-10-05 Neurogesx, Inc. Timbre transdermique a faible concentration de capsaicine et procedes de traitement des douleurs neuropathiques
US9114127B2 (en) * 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
ES2097783T3 (es) * 1991-01-15 1997-04-16 Hemosphere Inc Nanomatrices proteicas y procedimiento de produccion.

Similar Documents

Publication Publication Date Title
WO1996040075B1 (fr) Procede de production a grande echelle avec melange instantane des composants et caracteristiques controlees de melange sequentiel
Azzi et al. A fluorescence probe of energy-dependent structure changes in fragmented membranes
Farquhar et al. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection
US6270802B1 (en) Method and apparatus for formulating microspheres and microcapsules
Keenan et al. An altered response by peripheral leukocytes to synthesize or release leukocyte endogenous mediator in critically ill, protein-malnourished patients
Schachter et al. Asymmetry of lipid dynamics in human erythrocyte membranes studied with permeant fluorophores
Simplicio et al. Hemin intercalated in micellar cetyltrimethylammonium bromide and Triton X-100. Kinetic, spectral, and equilibrium study with cyanide
US6013285A (en) Large scale production process with instantaneous component mixing and controlled sequential mixing characteristics
US20030159953A1 (en) Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof
Cooper et al. Free ribosomes in physiologically nondividing cells. Human peripheral lymphocytes.
Levy et al. Effect of complex formation on drug absorption II. Lipoid‐soluble dye complexes
Firey et al. Photochemical properties of erythrocyte ghosts containing porphyrin
Frederiksen Cardiopulmonary bypass in humans: bypassing unfractionated heparin
Kishi et al. Vitamin A and E requirements during total parenteral nutrition
Darcy-Vrillon et al. Analysis of sequential events in intestinal absorption of folylpolyglutamate
NO20002008L (no) Løsning for peritonealdialyse og fremgangsmÕte for fremstilling derav
Christensen Hypothesis: Control of hepatic utilization of alanine by membrane transport or by cellular metabolism? Review
JPH01199158A (ja) 赤血球保存液
US3919414A (en) Accelerating the lysis of blood clots
NO904119L (no) Trombolytisk materiale inneholdende vevstypeplasminogenaktivator eller derivat derav.
Yamamoto et al. Intermolecular energy transfer of the spin polarized triplet state in frozen SDS micelles
Yasuhara et al. Comparative studies on the absorption mechanism of p-aminobenzoic acid and p-acetamidobenzoic acid from the rat intestine
Owen et al. Urea production and excretion by the chicken kidney
CN100360938C (zh) 甾体类激素-碱性磷酸酶结合物制备方法
CN101618023B (zh) 一种制备微粉化蛋白的方法